Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.

Article  PubMed  PubMed Central  Google Scholar 

Kulke M, Benson A, Bergsland E, Berlin J, Blaszkowsky L, Choti M, Clark O, Doherty G, Eason J, Emerson L, et al. Neuroendocrine tumors. J Natl Compr Canc Netw. 2012;10:724–64.

Article  CAS  PubMed  Google Scholar 

Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B, Salazar R. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–76.

Article  CAS  PubMed  Google Scholar 

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin oncology: official J Am Soc Clin Oncol. 2008;26(18):3063–72.

Article  Google Scholar 

Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, Fazio N, Giammarile F, Hicks RJ, Kjaer A, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology. 2017;105(3):212–44.

Article  CAS  PubMed  Google Scholar 

Schreiter NF, Nogami M, Steffen I, Pape UF, Hamm B, Brenner W, Röttgen R. Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours. Eur Radiol. 2012;22(2):458–67.

Article  PubMed  Google Scholar 

Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin oncology: official J Am Soc Clin Oncol. 2009;27(28):4656–63.

Article  CAS  Google Scholar 

Swiha MM, Sutherland DEK, Sistani G, Khatami A, Abazid RM, Mujoomdar A, Wiseman DP, Romsa JG, Reid RH, Laidley DT. Survival predictors of (177)Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS). J Cancer Res Clin Oncol. 2022;148(1):225–36.

Article  CAS  PubMed  Google Scholar 

Panzuto F, Pusceddu S, Faggiano A, Rinzivillo M, Brighi N, Prinzi N, Riccardi F, Iannicelli E, Maggio I, Femia D, et al. Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: a comparison between pancreatic and gastrointestinal localizations. Pancreatology. 2019;19(8):1067–73.

Article  PubMed  Google Scholar 

Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8–21.

Article  PubMed  Google Scholar 

Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–8.

Article  PubMed  Google Scholar 

Rufini V, Baum RP, Castaldi P, Treglia G, De Gaetano AM, Carreras C, Kaemmerer D, Hommann M, Hörsch D, Bonomo L, et al. Role of PET/CT in the functional imaging of endocrine pancreatic tumors. Abdom Imaging. 2012;37(6):1004–20.

Article  PubMed  Google Scholar 

Liu X, Li N, Jiang T, Xu H, Ran Q, Shu Z, Wu J, Li Y, Zhou S, Zhang B. Comparison of gallium-68 somatostatin receptor and (18)F-fluorodeoxyglucose positron emission tomography in the diagnosis of neuroendocrine tumours: a systematic review and meta-analysis. Hell J Nucl Med. 2020;23(2):188–200.

CAS  PubMed  Google Scholar 

Majala S, Vesterinen T, Seppänen H, Mustonen H, Sundström J, Schalin-Jäntti C, Gullichsen R, Schildt J, Kemppainen J, Arola J et al. Correlation of Somatostatin Receptor 1–5 Expression, [(68)Ga]Ga-DOTANOC, [(18)F]F-FDG PET/CT and Clinical Outcome in a Prospective Cohort of Pancreatic Neuroendocrine Neoplasms. Cancers 2021, 14(1).

Ambrosini V, Zanoni L, Filice A, Lamberti G, Argalia G, Fortunati E, Campana D, Versari A, Fanti S. Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors. Cancers 2022, 14(4).

Beyer L, Gosewisch A, Lindner S, Völter F, Mittlmeier LM, Tiling R, Brendel M, Cyran CC, Unterrainer M, Rübenthaler J, et al. Dosimetry and optimal scan time of [(18)F]SiTATE-PET/CT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2021;48(11):3571–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ilhan H, Lindner S, Todica A, Cyran CC, Tiling R, Auernhammer CJ, Spitzweg C, Boeck S, Unterrainer M, Gildehaus FJ, et al. Biodistribution and first clinical results of (18)F-SiFAlin-TATE PET: a novel (18)F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2020;47(4):870–80.

Article  CAS  PubMed  Google Scholar 

Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, et al. NCCN Guidelines Insights: neuroendocrine and adrenal tumors, Version 2.2018. J Natl Compr Cancer Network: JNCCN. 2018;16(6):693–702.

Article  CAS  Google Scholar 

Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, Ambrosini V, Kjaer A, Delgado-Bolton R, Kunikowska J, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44(9):1588–601.

Article  CAS  PubMed  Google Scholar 

Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C, Falconi M, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J cancer (Oxford England: 1990). 2021;146:56–73.

Article  CAS  Google Scholar 

Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, Berruti A. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology. 2020;31(7):844–60.

Article  CAS  PubMed  Google Scholar 

Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, de Herder WW, Hörsch D, Knigge U, et al. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(☆). Annals of oncology: official journal of the European Society for Medical Oncology. 2021;32(4):439–51.

Article  CAS  PubMed  Google Scholar 

Rinke A, Wiedenmann B, Auernhammer C, Bartenstein P, Bartsch DK, Begum N, Faiss S, Fottner C, Gebauer B, Goretzki P, et al. Practice guideline neuroendocrine tumors - AWMF-Reg. Z Gastroenterol. 2018;56(6):021–27.

Google Scholar 

Zidan L, Iravani A, Kong G, Akhurst T, Michael M, Hicks RJ. Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on (68)Ga-DOTATATE PET/CT and (18)F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2021;48(1):204–16.

Article  CAS  PubMed  Google Scholar 

Moryoussef F, de Mestier L, Belkebir M, Deguelte-Lardière S, Brixi H, Kianmanesh R, Hoeffel C, Cadiot G. Impact of liver and whole-body diffusion-weighted MRI for neuroendocrine tumors on Patient Management: a pilot study. Neuroendocrinology. 2017;104(3):264–72.

Article  CAS  PubMed  Google Scholar 

d’Assignies G, Fina P, Bruno O, Vullierme MP, Tubach F, Paradis V, Sauvanet A, Ruszniewski P, Vilgrain V. High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. Radiology. 2013;268(2):390–9.

Article  PubMed  Google Scholar 

Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg. 2009;96(2):175–84.

Article  CAS  PubMed  Google Scholar 

Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, Di Fonzo M, Tornatore V, Milione M, Angeletti S, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocrine-related Cancer. 2005;12(4):1083–92.

Article  PubMed  Google Scholar 

Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF, Vilgrain V, Belghiti J, Bernades P, Ruszniewski P. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998;43(3):422–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jackson T, Darwish M, Cho E, Nagatomo K, Osman H, Jeyarajah DR. 68Ga-DOTATATE PET/CT compared to standard imaging in metastatic neuroendocrine tumors: a more sensitive test to detect liver metastasis? Abdom Radiol (New York). 2021;46(7):3179–83.

Article  Google Scholar 

Armbruster M, Zech CJ, Sourbron S, Ceelen F, Auernhammer CJ, Rist C, Haug A, Singnurkar A, Reiser MF, Sommer WH. Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms. J Magn Reson imaging: JMRI. 2014;40(2):457–66.

Article  PubMed  Google Scholar 

Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, Pacak K, Marx SJ, Kebebew E. Prospective study of 68Ga-DOTATATE Positron Emission Tomography/Computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary Sites. J Clin oncology: official J Am Soc Clin Oncol. 2016;34(6):588–96.

Article  CAS  Google Scholar 

Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, Li J, Broelsch CE. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010;252(5):850–6.

Article  PubMed  Google Scholar 

Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol. 2012;56(1):40–7.

Article  PubMed  Google Scholar 

Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, Eiber M, Herrmann K, Fendler WP. The impact of somatostatin Receptor-Directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and Meta-analysis. J nuclear medicine: official publication Soc Nuclear Med. 2017;58(5):756–61.

Article  Google Scholar 

Froelich MF, Schnitzer ML, Holzgreve A, Gassert FG, Gresser E, Overhoff D, Schwarze V, Fabritius MP, Nörenberg D, von Münchhausen N, et al. Cost-effectiveness analysis of 68Ga DOTA-TATE PET/CT, 111In-Pentetreotide SPECT/CT and CT for diagnostic workup of neuroendocrine tumors. Diagnostics. 2021;11(2):334.

Article